Vupanorsen, an inhibitor of ANGPTL3, was also studied in a recent analysis conducted on four patients with FPLD (two with pathogenic variants in the LMNA gene), severe hypertriglyceridaemia and hepatic steatosis. Here, ANGPTL3 is linked to fatty liver disease.